Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Buildings: 2010-2023

Historic Buildings for China Pharma Holdings (CPHI) over the last 12 years, with Jun 2023 value amounting to $9.1 million.

  • China Pharma Holdings' Buildings fell 7.12% to $9.1 million in Q2 2023 from the same period last year, while for Jun 2023 it was $9.1 million, marking a year-over-year decrease of 7.12%. This contributed to the annual value of $9.4 million for FY2022, which is 8.46% down from last year.
  • China Pharma Holdings' Buildings amounted to $9.1 million in Q2 2023, which was down 4.90% from $9.5 million recorded in Q1 2023.
  • In the past 5 years, China Pharma Holdings' Buildings ranged from a high of $10.3 million in Q1 2022 and a low of $9.1 million during Q2 2023.
  • In the last 3 years, China Pharma Holdings' Buildings had a median value of $9.7 million in 2022 and averaged $9.7 million.
  • Its Buildings has fluctuated over the past 5 years, first climbed by 9.59% in 2021, then fell by 8.65% in 2022.
  • Quarterly analysis of 5 years shows China Pharma Holdings' Buildings stood at $9.4 million in 2019, then grew by 6.92% to $10.0 million in 2020, then climbed by 2.34% to $10.3 million in 2021, then dropped by 8.46% to $9.4 million in 2022, then dropped by 7.12% to $9.1 million in 2023.
  • Its Buildings was $9.1 million in Q2 2023, compared to $9.5 million in Q1 2023 and $9.4 million in Q4 2022.